Pharma News: VIVUS, Inc. (VVUS)’s Injury, Arena Pharmaceuticals, Inc. (ARNA) & Amgen, Inc. (AMGN)’s Agreement
The ratings of four Pharmaceutical stocks are down this week, according to the Portfolio Grader database.
Posts Tagged ‘NASDAQ:AMGN’
Onyx Pharmaceuticals, Inc. (ONXX), Amgen, Inc. (AMGN), Alexion Pharmaceuticals, Inc. (ALXN): Biotech’s Falling Fortunes Stymie Osiris Therapeutics, Inc. (OSIR)’s Huge Week
Biotech's the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling up or down by significant amounts...
Pharma News: VIVUS, Inc. (VVUS) Qsymia Patents, Arena Pharmaceuticals, Inc. (ARNA) Earnings, Amgen, Inc. (AMGN) Ending an Agreement
Earlier today RFD IP Business Services ("RFD") released a new report analyzing the likely inequitable conduct challenges to VIVUS, Inc.
Amgen, Inc. (AMGN), Corning Incorporated (GLW): Top Stocks Growing Their Dividends By 25% Per Year
Dividend investors would be wise to focus not just on a stock's current yield, but also on the long-term growth potential of its dividends.
GlaxoSmithKline plc (ADR) (GSK), Roche Holding Ltd. (ADR) (RHHBY): Why Alex Rodriguez Could Bring Big Business to This Sector
Baseball star Alex Rodriguez had an opportunity to be perhaps the greatest player of the past decade or even longer -- that was until he threw it all away by admitting to steroid...
Amgen, Inc. (AMGN), Pfizer Inc. (PFE), Merck & Co., Inc. (MRK): A Closer Look at the Battle Over Cancer Treatments
Over the past year, the battle over cancer treatments has heated up considerably. Big pharma companies such as Amgen, Inc. (NASDAQ:AMGN), Pfizer Inc.
Aegerion Pharmaceuticals, Inc. (AEGR), ISIS Pharmaceuticals, Inc. (ISIS), Sanofi SA (ADR) (SNY): This Is One Incredible CEO
The Motley Fool's readers have spoken, and I have heeded their cries.
Pfizer Inc. (PFE), Amgen, Inc. (AMGN): The Best-Selling Medications of 2013 (So Far)
Believe it or not, 2013 is getting close to being two-thirds of the way over. Many pharmaceutical firms have enjoyed great stock returns and nice profits thus far in the year.
3 Things You Need to Know From Vical Incorporated (VICL)’s Q2 Results
Vical Incorporated (NASDAQ:VICL) announced its second-quarter results on Thursday.
Amgen, Inc. (AMGN), Baxter International Inc. (BAX): Can the FDA Make Up Its Mind Already?
It isn't very often that an agency sometimes accused of over-regulating an industry can be ridiculed for not regulating enough, but that's exactly where the Food and Drug Administration...
Three Things You Need to Know From Keryx Biopharmaceuticals (KERX)’s Q2 Earnings
Keryx Biopharmaceuticals (NASDAQ:KERX) announced its second-quarter results before the market opened on Thursday.
Is More Patent Pain Headed Merck & Co., Inc. (MRK)’s Way?
Merck & Co., Inc. (NYSE:MRK) might be one of big pharma's largest companies, but this health care leader has had a tough go recently.
Pharma News: Vivus, Inc. (VVUS)’s New CEO, Arena Pharmaceuticals, Inc. (ARNA) & Amgen, Inc. (AMGN)’s Positive Earnings
VIVUS, Inc. (NASDAQ:VVUS), which sells the obesity drug Qsymia, has appointed Anthony Zook to serve as its CEO.
Amgen, Inc. (AMGN), QUALCOMM, Inc. (QCOM): Investing in Growth Stocks — With Ease
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you.
Amgen, Inc. (AMGN), Gilead Sciences, Inc. (GILD): Great Pipelines, Unimpressive Fundamentals
Biotechnology medicine manipulates the genetic material of living organisms to produce pharmaceuticals, which in many instances are designed to combat diseases once considered...
Onyx Pharmaceuticals, Inc. (ONXX), Amgen, Inc. (AMGN): Will This Biotech Bidding War Lead You to Larger Gains?
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) added 3% to its one-month 60% gains on Monday because of continued speculation of a buyout.
Amgen, Inc. (AMGN), Celgene Corporation (CELG): Is Big Biotech Still Growing?
The first half of 2013 has seen remarkable growth in the biotech sector, with the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) up >40% YTD. The industry continues to...
Onyx Pharmaceuticals, Inc. (ONXX), Amgen, Inc. (AMGN): Why Getting Rich Quick Doesn’t (Always) Pay
We have a bona fide biotech soap opera going on these days. Spurned love. Possible romance. Disgruntled suitor. And, of course, the unknown villain.
Amgen, Inc. (AMGN)’s Acquisition Ambition Leads Biotechs’ Rise
Biotech's the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling up or down by significant amounts...
Google Inc (GOOG), Xerox Corporation (XRX) – Wall Street’s Secret Weapon: Women
Times have changed, and women are stepping in to close the gender gap in corporate America.
Celgene Corporation (CELG): Expanding Labels to Expand Margins
In an industry where buyouts are commonplace and small-cap biotechs burn through cash rapidly, optimizing operating cash flow can be essential to a company's financial health.
Four Potential Suitors for Onyx Pharmaceuticals, Inc. (ONXX)
The "people familiar with the matter" are out in full force spouting off about who's bidding for Onyx Pharmaceuticals, Inc.
Merck & Co., Inc. (MRK)’s Late-Stage Breakdown
The Food and Drug Administration cancelled an advisory meeting planned for Merck & Co., Inc. (NYSE:MRK)’s post-surgery drug sugammadex.
A Look at Novartis AG (ADR) (NVS)’ Second Quarter
The story of the second quarter for Novartis AG (ADR) (NYSE:NVS) offered mixed results for investors. The company's net sales were up 1%, and EPS was down 6% year over year.
Onyx Pharmaceuticals, Inc. (ONXX), Alexion Pharmaceuticals, Inc. (ALXN): 3 Biotechs That Could Be Bought Out This Year
Chances are that a few biotech companies will be scooped up by larger players over the coming months.
Amgen, Inc. (AMGN), Hospira, Inc. (HSP): How Valuable Is a Cheaper Treatment for Arthritis?
Arthritis biologics like Remicade, Enbrel, and Humira are pricy drugs that many of the 50 million American arthritis patients – and hundreds of millions of patients worldwide...
Who Is the Best Suitor for Onyx Pharmaceuticals, Inc. (ONXX)?
Cancer-drug maker Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) recently rejected an $8.7 billion unsolicited acquisition offer from Amgen, Inc. (NASDAQ:AMGN).
AbbVie Inc (ABBV), Amgen, Inc. (AMGN): Do Generic Drugs Drastically Alter Market Dynamics?
Pharma companies have been paying off generic drug makers so that cheap generic drugs do not enter the market. In a settlement case involving AbbVie Inc (NYSE:ABBV), the U.S.
Amgen, Inc. (AMGN) Stirs the Pot in the Cancer-Related Sector
Several companies are fighting to be the first to release a treatment or cure for cancer that is a game-changer, and this battle has created a field where firms are looking to...
Onyx Pharmaceuticals, Inc. (ONXX), Celldex Therapeutics, Inc. (CLDX): Three Humongous Health-Care Stocks This Week
While many American skies were lit up with fireworks this week, the stock market also saw its share of pops, sizzles, and bangs.
How Much Is Onyx Pharmaceuticals, Inc. (ONXX) Really Worth?
The promising cancer developer confirmed over the weekend that Amgen had made an offer to acquire Onyx for $120 per share, a 38.2% premium above Friday's close.
Amgen, Inc. (AMGN), Celgene Corporation (CELG), Biogen Idec Inc. (BIIB): Watch Out for These 3 Biotech Companies
This year, the North American players in the biotechnology industry are expected to spend $15 billion.
Amgen, Inc. (AMGN), Onyx Pharmaceuticals, Inc. (ONXX): Is This Biopharmaceutical Stock Still a Buy?
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) has recently experienced a significant jump of nearly 51.3% in only one trading day from $86.82 per share to $131.30 per share.
Wells Fargo & Co (WFC), Baxter International Inc. (BAX): Obamacare-Inspired Investment Opportunities
Love it or hate it, the Patient Protection and Affordable Care Act -- commonly referred to as Obamacare -- changes the health care landscape.
Onyx Pharmaceuticals, Inc. (ONXX), Amgen, Inc. (AMGN): Is This A Good Acquisition For All?
For the second day in a row, the hot topic in the market is the bidding war for Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX). After rejecting Amgen, Inc.
Amgen, Inc. (AMGN), Onyx Pharmaceuticals, Inc. (ONXX): Avoid This Biotech Investment, For Now
Mergers and acquisitions have always been a big part of the biotechnology industry, and the patent cliff has further increased M&A activity.
Onyx Pharmaceuticals, Inc. (ONXX) Bidding Wars: Who Would Be the Best Suitor?
Recently, Amgen, Inc. (NASDAQ:AMGN) made a surprisingly low offer to acquire the pharmaceutical company Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX).
Immunomedics, Inc. (IMMU), ImmunoGen, Inc. (IMGN): Should You Invest in These Cancer Treatment Biotechs?
Today, cancer is the second leading cause of death in the United States, accounting for nearly a quarter of all deaths in the country.
Quiksilver, Inc. (ZQK), Pfizer Inc. (PFE): Tuesday’s Top Upgrades (and Downgrades)
This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on.
Onyx Pharmaceuticals, Inc. (ONXX) Says the Price Isn’t Right
That's the message from Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) over the weekend after Amgen, Inc. (NASDAQ:AMGN) made an unsolicited offer to buy the company.
United Technologies Corporation (UTX), Travelers Companies Inc (TRV): Will These Unlikely Winners Keep Leading the Dow Higher?
After a strong performance during the first half of the year, the Dow Jones Industrials added to its 2013 gains with a 65-point gain.
Amgen, Inc. (AMGN) vs. Big Pharma: It’s Amgen for the Long Term
Over the last three decades I have seen my share of bull and bear markets.
Amgen, Inc. (AMGN)’s Future Is Bright
Amgen, Inc. (NASDAQ:AMGN) has gone up a lot in share price over the last few years. Amgen, Inc.
Three Things That Will Move AbbVie Inc (ABBV) Stock
AbbVie Inc (NYSE:ABBV) has risen more than 20% since it hit the market earlier this year. In fact, it has managed to beat the S&P 500 by nearly 10%.
Gilead Sciences, Inc. (GILD), Celgene Corporation (CELG): Biting Into Biotechnology
Global equity markets have been rocked recently as fears of rising interest rates and tightening monetary possible make their way into the minds of the street.
Amgen, Inc. (AMGN): The Only True Biotech Dividend Stock
Dividend stocks are hard to come by in the biotech space.
Time to Buy Amgen, Inc. (AMGN)?
A double-digit drop for Amgen, Inc. (NASDAQ:AMGN) stock over the past couple of months has likely left a bad taste in the mouths of shareholders.
Biogen Idec Inc. (BIIB), Alexion Pharmaceuticals, Inc. (ALXN): Best-Run Biotech Companies
Which biotech companies are the best-run? That could be a difficult question to answer, since there are many perspectives on what constitutes a well-run company.
Merck & Co., Inc. (MRK), Pfizer Inc. (PFE): Top Treatments for High Cholesterol
About a third of American adults have high LDL cholesterol -- that's the bad kind -- but less than half of adults with high LDL seek treatment, according to the Centers for Disease...
